Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB147 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MAD: Cohort A | EXPERIMENTAL | Participants will either receive Dose A of BIIB147 or a placebo for 12 weeks. |
| MAD: Cohort B | EXPERIMENTAL | Participants will either receive Dose B of BIIB147 or a placebo for 12 weeks. |
| MAD: Cohort C | EXPERIMENTAL | Participants will either receive Dose C of BIIB147 or a placebo for 12 weeks. |
| MAD: Cohort D | EXPERIMENTAL | Participants will either receive Dose D of BIIB147 or a placebo for 20 weeks. |
| OLE | EXPERIMENTAL | Participants from Cohorts A-D who complete the MAD period will enter a 4-week blinded loading-dose period. During this period, participants randomized to BIIB147 in the MAD period will receive placebo, followed by BIIB147, while participants randomized to placebo during the MAD period will receive BIIB147. Upon completion of the blinded loading-dose period, all participants will enter the open-label maintenance dose period and receive BIIB147 for up to 340 weeks. |
| Name | Type | Description |
|---|---|---|
| BIIB147 | DRUG | Administered intrathecally (IT) |
| Placebo | DRUG | Administered IT |
Key Inclusion Criteria: MAD Period * Participants must have a diagnosis of ALS consistent with the Gold Coast criteria. * No pathogenic variants, likely pathogenic variants, or variants of uncertain significance in the superoxide dismutase 1 (SOD1) or fused in sarcoma (FUS) genes (confirmed by cen...
BIIB147 is an investigational small molecule being developed by Biogen for amyotrophic lateral sclerosis (ALS). It is in Phase 1 clinical development and is not approved for any use. The only study listed for BIIB147 enrolls adults with ALS in the United States.
BIIB147 is being developed by Biogen Inc., which trades on Nasdaq under the ticker BIIB. Biogen is the sponsor of the Phase 1 study of BIIB147 in amyotrophic lateral sclerosis, which is currently recruiting participants in the United States.
BIIB147 is in Phase 1 clinical development. It is an investigational small molecule for amyotrophic lateral sclerosis and is not approved by the FDA. One Phase 1 trial is currently recruiting, and no completed trials of BIIB147 are listed.
BIIB147 is being studied in one Phase 1 trial, NCT07855211, titled A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS). The trial is recruiting up to 69 adults aged 18 and older in the United States and is randomized, double-blind, and controlled.
Yes. The Phase 1 trial of BIIB147, NCT07855211, is biomarker-selected, meaning enrollment is guided by a biomarker. The study is randomized, double-blind, and controlled, and it enrolls adults with amyotrophic lateral sclerosis rather than healthy volunteers, with a planned enrollment of 69 participants.